An Open Label Observational Study of Safety and Efficacy of a Pharmaceutical grade Cannabis Medicine (MediCabilis™-CBD extract Oil) in Patients undergoing Medicinal Cannabis Therapy for Different Indications
Type of Study/Intervention
Form of MS
People with any form of MS or symptoms related to MS that Bod medicinal cannabis treatment is approved for (through the TGA’s special access scheme) are eligible for participation.
This study is a nation-wide observational study aiming to assess the safety, tolerability and efficacy of a non-intoxicating cannabidiol-dominant medicinal cannabis in managing chronic conditions that haven’t responded well to traditional treatment options, including multiple sclerosis.
Patients who are prescribed Bod medicinal cannabis and meet the eligibility criteria will be able to participate in this important observational study.
Participation in the study involves periodically completing online questionnaires on health outcomes and response to the medication using the study app or website for the duration of the study (up to 12 months). Patients who participate will receive their first two bottles of medicine that are prescribed as complementary, and the medicines prescribed for the remainder of the study (up to 12 months) will be discounted. Pharmacy dispensing costs (typically no more than $30) and clinic consultation fees apply.
Patients (18+) who are prescribed Bod medicines for an approved indication and meet the eligibility criteria will be invited to participate in this study.
For full details of inclusion/exclusion see here.
Any severe cognitive, intellectual disability, medical or psychiatric condition that impairs the participant’s ability to provide informed consent. Patients who are using illicit forms of cannabis.
Anticipated Start Date
Study began in July 2020 and we expect recruitment to close 30 June 2021
Please contact Bod at firstname.lastname@example.org or on 0429 508 190
This study was approved by the Bellberry Ethics Committee on 13/05/2020 (ethics approval number, 2020-02-174).
25 May 2021